FOXP1 and cancer: Furthermore, analysis of ICB therapy datasets suggested that cancer patients with low FOXP1 expression demonstrated higher ICB response rates and improved survival outcomes, including OS and progression-free survival in comparison to cancer patients with high FOXP1 expression.